Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria (NASDAQ:LEXX) announced final results from Human Pilot Study #5 comparing oral DehydraTECH-liraglutide (DHT-LIR) capsules to injected Saxenda® (SAX-LIR) liraglutide. The Study met its primary safety and tolerability endpoint, reporting a 22.7% reduction in adverse events with DHT-LIR, including 67% less nausea and 31% fewer GI adverse events.
Pharmacokinetic blood quantitation faced assay background noise challenges, limiting PK conclusions to exploratory ELISA signal visualizations that showed broadly similar temporal patterns between treatments. Lexaria is exploring a 505(b)(2) regulatory pathway and potential collaborations to develop an oral liraglutide product.
Lexaria (Nasdaq:LEXX) announced six newly granted patents, bringing its total to 60 granted patents across major global markets as of January 22, 2026.
The six grants include: Australia (first patent) for Family #20 (sublingual nicotine); EU (first patent) for Family #21 (hypertension); two Australia and one EU patents for Family #24 (epilepsy); and one new US patent for Family #27 (diabetes), bringing that family to two US patents.
Shareholders are reminded to vote at the Annual Meeting on January 27, 2026 at 1:00 PM PT.
Lexaria (Nasdaq:LEXX) CEO published the company's 2025 annual letter on January 12, 2026, summarizing R&D, clinical, patent and financing progress. Key facts: Lexaria completed a Phase 1b registrational study in Australia with primary endpoints met and a 48% reduction in total adverse events for the DHT-semaglutide arm versus Rybelsus®; earlier pilot studies showed 47% AE reduction for DHT-tirzepatide and 23% AE reduction for DHT-liraglutide. Lexaria also completed a rodent biodistribution study showing higher brain signal for DHT-processed semaglutide, was granted 10 patents (totaling 56 worldwide), extended an MTA with a pharma partner through April 30, 2026, and raised $9.5M in 2025.
Lexaria (NASDAQ:LEXX) published additional final results from its Phase 1b 12-week study GLP-1-H24-4 (126 subjects) comparing four DehydraTECH (DHT) arms to a Rybelsus® control.
Primary endpoint met: DHT test articles showed good safety and tolerability with reductions in total and GI adverse events versus Rybelsus®. Notable secondary/exploratory findings include body-composition differences, sustained plasma CBD and tirzepatide detectability, and meaningful blood pressure reductions in the DHT-CBD arm.
Lexaria (Nasdaq:LEXX) announced that its Phase 1b study GLP-1-H24-4 met its primary endpoint for safety and tolerability, with DehydraTECH formulations showing lower adverse events versus the Rybelsus control.
Key findings: DehydraTECH-semaglutide reduced overall side effects ~48% and gastrointestinal side effects ~55% versus Rybelsus; DHT-semaglutide showed a 47.9% reduction in total AEs versus Rybelsus. HbA1c reductions were comparable to Rybelsus (p>0.05). Rybelsus produced larger bodyweight reductions (Wk12: -5.29 kg, EOS Wk16: -4.95 kg) than DHT arms.
Lexaria raised a gross $7.5 million after fiscal year-end to fund prospective 2026 development and will share the dataset with its MTA partner; the MTA was extended through April 30, 2026.
Lexaria Bioscience (NASDAQ:LEXX) closed a registered direct offering of 2,661,600 common shares at $1.315 per share and concurrently issued unregistered warrants to purchase up to 2,661,600 shares.
The warrants carry a $1.19 exercise price, are immediately exercisable and expire five years after the resale registration statement became effective. Aggregate gross proceeds were approximately $3.5 million, before placement agent fees and expenses. H.C. Wainwright acted as exclusive placement agent. Net proceeds are intended for R&D, working capital and general corporate purposes.
Lexaria Bioscience (NASDAQ:LEXX) announced a registered direct offering of 2,661,600 shares of common stock at $1.315 per share, with aggregate gross proceeds expected to be approximately $3.5 million before fees and expenses. The offering is priced at-the-market under Nasdaq rules and is expected to close on or about December 16, 2025, subject to customary conditions.
In a concurrent private placement the company will issue unregistered warrants to purchase up to 2,661,600 shares at an exercise price of $1.19 per share; the warrants are immediately exercisable and expire five years after effectiveness of the resale registration statement. H.C. Wainwright & Co. is sole placement agent. Net proceeds are intended for R&D, working capital and general corporate purposes.
Lexaria Bioscience (NASDAQ:LEXX, LEXXW) entered a definitive agreement for a registered direct offering of 2,666,667 common shares at $1.50 per share and a concurrent private placement of unregistered warrants to purchase up to 2,666,667 shares.
The warrants carry a $1.37 exercise price, are immediately exercisable and expire five years from the effectiveness of the resale registration statement. Aggregate gross proceeds are expected to be approximately $4.0 million before placement agent fees and expenses. The closing is expected on or about September 29, 2025, subject to customary conditions.
Proceeds are intended for working capital and general corporate purposes; the registered shares are offered under an effective Form S-3 shelf registration.
Lexaria (Nasdaq:LEXX) announced an extension to its Material Transfer Agreement with a pharmaceutical company through April 30, 2026 to allow PharmaCO time to receive and review the full dataset from Lexaria's Australian human study GLP-1-H24-4.
The extension keeps the temporary exclusive license active and preserves the parties' ability to continue strategic planning with PharmaCO's human clinical development team. Lexaria said initial pre-clinical pharmacokinetic animal studies under the MTA were completed earlier in 2025 and that final results from the Australian study are projected to be released before the end of Q4 2025.
Lexaria Bioscience (NASDAQ:LEXX) announced strategic updates including engagement of a global life‑science business development advisory firm, completion of an equity financing raising $4.0 million gross, and award of 4 new patents covering diabetes, epilepsy, antiviral delivery and infused food/beverage applications (grant dates Jul–Oct 2025).
The funding extends operations beyond 2025, supports expanded R&D into 2026, and enables increased outreach to pharmaceutical and biotech partners. Final results from a Phase 1b Australian GLP‑1 study are anticipated and further R&D budget decisions will be announced later.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
